DrugPatentWatch Database Preview
Investigational Drug Information for BGG492
Email this page to a colleague
What is the development status for investigational drug BGG492?
BGG492 is an investigational drug.
There have been 10 clinical trials for BGG492.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2009.
The most common disease conditions in clinical trials are Seizures, Migraine Disorders, and Epilepsy. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and [disabled in preview].
Summary for BGG492
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 42 |
| WIPO Patent Applications | 13 |
| Japanese Patent Applications | 11 |
| Clinical Trial Progress | Phase 2 (2009-04-01) |
| Vendors | 8 |
Recent Clinical Trials for BGG492
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis | Novartis Pharmaceuticals | Phase 2 |
| A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention | Novartis Pharmaceuticals | Phase 2 |
| Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 | Novartis Pharmaceuticals | Phase 2 |
Clinical Trial Summary for BGG492
Top disease conditions for BGG492
Top clinical trial sponsors for BGG492
US Patents for BGG492
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
